Business Context and Reporting Period
Company: TransCode Therapeutics, Inc. (Nasdaq: RNAZ)
Filing Type: Form 8-K (Current Report)
Date of Report: April 6, 2026
Reporting Period: Event-driven filing regarding material agreements entered into on April 6, 2026.
Key Financial Metrics and Agreements
This filing details a Standby Equity Purchase Agreement (SEPA) and related convertible notes with YA II PN, LTD ("Yorkville"), alongside a payment-in-kind (PIK) dividend issuance.
- SEPA Commitment: Yorkville agreed to purchase up to $14 million of common stock at the Company's discretion.
- Pricing Mechanism: Purchase price set at 97% of the lowest daily VWAP during a three-day pricing period.
- Pre-Paid Advances (Convertible Notes):
- Tranche 1: $1.0 million principal (net proceeds ~$950,000 after 5% discount). Convertible at 115% of prior day VWAP or 95% of lowest 7-day VWAP (subject to floor price).
- Tranche 2: $5.0 million principal (net proceeds ~$4.75 million after 5% discount). Similar conversion terms.
- Interest Rate: 5.0% annually, increasing to 18% upon default.
- Maturity: 18 months from issuance (extendable twice by 6 months).
- Fees: $25,000 diligence fee paid; $280,000 commitment fee (2% of commitment) due within 30 days or upon registration filing.
- PIK Dividend: Issued 28.4291 shares of Series A Preferred Stock to DEFJ and 1.4604 shares to Tungsten Advisors on April 6, 2026, accruing at 5% per annum.
Material Changes and Conditions
The filing represents a significant change in the Company's capital structure and liquidity options.
- Liquidity Access: Establishment of a $14 million equity line of credit, providing flexible funding subject to market conditions.
- Dilution Caps: Issuance is capped at 19.99% of outstanding shares (183,301 shares) unless stockholder approval is obtained. Yorkville is also limited to 9.99% ownership unless notice is given.
- Conditions Precedent: The $1.0 million tranche is conditioned on the timely filing of the 2025 Form 10-K by April 15, 2025 (note: filing date in text appears to be a typo relative to the 2026 report date, but stated as condition). The $5.0 million tranche requires an effective registration statement, stockholder approval for excess issuance, and Nasdaq listing approval.
- Default Provisions: Events of default (e.g., payment default, bankruptcy, late SEC reports) trigger an interest rate hike to 18% and immediate acceleration of debt with a 10% premium.
Outlook, Risks, and Management Commentary
Management Commentary: The Company views the SEPA as a strategic tool to secure funding for business operations and acquisitions, with sales timing at the Company's sole discretion based on market conditions.
Risks and Contingencies:
- Stockholder Approval: The Company must seek stockholder approval to issue shares exceeding the 19.99% exchange cap.
- Registration Timeline: The Company must file a registration statement by April 30, 2026, and use commercially reasonable efforts to have it declared effective within 90 days.
- Market Volatility: The pricing mechanism (97% of lowest VWAP) and conversion floors may result in significant dilution if the stock price declines.
- Debt Obligations: The Convertible Notes carry a risk of acceleration and high interest rates if covenants are breached.
Investor Verification Checklist
- Verify the status of the 2025 Form 10-K filing to confirm the release of the $1.0 million tranche.
- Monitor the filing and effectiveness of the Yorkville Registration Statement (deadline: April 30, 2026).
- Review the upcoming proxy statement for the stockholder vote on the "Yorkville Issuance Proposal" to exceed the 19.99% exchange cap.
- Check Nasdaq listing approvals required for the issuance of shares under the SEPA.
- Assess the impact of the 5% purchase price discount and 97% VWAP pricing on current shareholder dilution.